Takaku F
Gan To Kagaku Ryoho. 1986 May;13(5):1823-8.
High-dose cytosine arobinoside (HDAra-C) was originally introduced in clinical hematology for the treatment of refractory or relapsed acute leukemia. Recently, however, this treatment has been tried for remission induction and/or consolidation in early leukemia cases, and resulted in a fairly percentage of long-term survival cases. HDAra-C in combination with anthracyclines is now considered to be a treatment which may afford some hope of a cure in a certain percentage of cases of adult acute non-lymphocytic leukemia. This treatment also has the advantage of being an effective treatment for meningeal leukemia, since a high concentration of Ara-C effective enough to kill leukemic cells is maintained in the cerebrospinal fluid after intravenous infusion of high-dose Ara-C. In this paper, the HDAra-C treatment of acute leukemia is reviewed and the results of our group study on the treatment of 30 cases of refractory acute leukemia with HDAra-C are discussed.
大剂量阿糖胞苷（HDAra-C）最初用于临床血液学中治疗难治性或复发性急性白血病。然而，最近这种治疗方法已被尝试用于早期白血病病例的诱导缓解和/或巩固治疗，并产生了相当比例的长期存活病例。HDAra-C与蒽环类药物联合使用，现在被认为是一种在一定比例的成人急性非淋巴细胞白血病病例中可能带来治愈希望的治疗方法。这种治疗方法还具有对脑膜白血病有效治疗的优势，因为在静脉输注高剂量阿糖胞苷后，脑脊液中可维持足以杀死白血病细胞的高浓度阿糖胞苷。本文对急性白血病的HDAra-C治疗进行了综述，并讨论了我们小组对30例难治性急性白血病进行HDAra-C治疗的研究结果。
